There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX), Encompass Health (EHC) and RegenXBio (RGNX) with bullish sentiments.
Boston Scientific (BSX)
In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on Boston Scientific, with a price target of $39.00. The company’s shares closed last Wednesday at $34.13.
According to TipRanks.com, Bedford is a 5-star analyst with an average return of 15.6% and a 70.8% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Integra Lifesciences.
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $43.14, implying a 26.8% upside from current levels. In a report issued on December 1, BTIG also maintained a Buy rating on the stock with a $41.00 price target.
See today’s analyst top recommended stocks >>
Encompass Health (EHC)
In a report released today, John Ransom from Raymond James maintained a Buy rating on Encompass Health. The company’s shares closed last Wednesday at $85.95.
According to TipRanks.com, Ransom is a 5-star analyst with an average return of 12.4% and a 65.4% success rate. Ransom covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, AmerisourceBergen, and Oak Street Health.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Encompass Health with a $86.17 average price target, representing a 1.1% upside. In a report released today, Credit Suisse also maintained a Buy rating on the stock with a $90.00 price target.
RegenXBio (RGNX)
Raymond James analyst Dane Leone maintained a Buy rating on RegenXBio today. The company’s shares closed last Wednesday at $38.93.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 17.2% and a 65.4% success rate. Leone covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Adverum Biotechnologies, and Tarsus Pharmaceuticals.
Currently, the analyst consensus on RegenXBio is a Strong Buy with an average price target of $65.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
